Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, USA.
Department of Biochemistry, Boston University School of Medicine, Boston, MA, USA; National Emerging Infectious Diseases Laboratories, Boston University, MA, USA.
Virology. 2021 Apr;556:73-78. doi: 10.1016/j.virol.2021.01.010. Epub 2021 Jan 26.
The need to stem the current outbreak of SARS-CoV-2 responsible for COVID-19 is driving the search for inhibitors that will block coronavirus replication and pathogenesis. The coronavirus 3C-like protease (3CLpro) encoded in the replicase polyprotein is an attractive target for antiviral drug development because protease activity is required for generating a functional replication complex. Reagents that can be used to screen for protease inhibitors and for identifying the replicase products of SARS-CoV-2 are urgently needed. Here we describe a luminescence-based biosensor assay for evaluating small molecule inhibitors of SARS-CoV-2 3CLpro/main protease. We also document that a polyclonal rabbit antiserum developed against SARS-CoV 3CLpro cross reacts with the highly conserved 3CLpro of SARS-CoV-2. These reagents will facilitate the pre-clinical evaluation of SARS-CoV-2 protease inhibitors.
遏制当前导致 COVID-19 的 SARS-CoV-2 爆发的需求,推动了对抑制剂的研究,这些抑制剂将阻断冠状病毒复制和发病机制。在复制酶多蛋白中编码的冠状病毒 3C 样蛋白酶(3CLpro)是抗病毒药物开发的一个有吸引力的靶点,因为蛋白酶活性是生成功能性复制复合物所必需的。迫切需要能够用于筛选蛋白酶抑制剂和鉴定 SARS-CoV-2 复制酶产物的试剂。在这里,我们描述了一种基于发光的生物传感器测定法,用于评估 SARS-CoV-2 3CLpro/主蛋白酶的小分子抑制剂。我们还证明了针对 SARS-CoV 3CLpro 制备的多克隆兔抗血清与 SARS-CoV-2 的高度保守 3CLpro 发生交叉反应。这些试剂将促进 SARS-CoV-2 蛋白酶抑制剂的临床前评估。